Holen Sie sich die Stockscreener-App
101.63
0.02%
-0.02
Handel nachbörslich:
101.47
-0.16
-0.16%
Schlusskurs vom Vortag:
$101.65
Offen:
$101.66
24-Stunden-Volumen:
2.60M
Relative Volume:
0.51
Marktkapitalisierung:
$19.29B
Einnahmen:
$2.83B
Nettoeinkommen (Verlust:
$-1.02B
KGV:
-18.44
EPS:
-5.51
Netto-Cashflow:
$194.14M
1W Leistung:
+0.07%
1M Leistung:
+0.56%
6M Leistung:
+93.65%
1J Leistung:
+77.99%
1-Tages-Spanne:
$101.55
$101.89
1-Wochen-Bereich:
$101.51
$102.05
52-Wochen-Spanne:
$38.81
$102.66
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
101.63 | 19.29B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
617.15 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.57 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
714.55 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.81 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
244.29 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize
Assessing Exact Sciences (EXAS) Valuation After A Strong Momentum-Driven Share Price Run - simplywall.st
EXAS Stock Rating Downgraded to 'In-Line' by Evercore ISI Group - GuruFocus
Abbott bets on cancer screening with $23 billion Exact Sciences deal - MSN
Pharma News: Can Exact Sciences Corporation EXK stock retain market dominanceVolume Spike & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
1 High-Flying Stock on Our Watchlist and 2 We Question - Finviz
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Exact Sciences Stock Is Going Wild: Is This Cancer-Test Giant a Hidden Gem or Total Trap? - AD HOC NEWS
19,260 Shares in Exact Sciences Corporation $EXAS Purchased by Strait & Sound Wealth Management LLC - MarketBeat
Exact Sciences Corp.: Turning DNA Into a Weapon Against Cancer - AD HOC NEWS
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
Alert from law firm on Exact Sciences-Abbott deal withdrawn - marketscreener.com
Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie ... - Bluefield Daily Telegraph
Should You Continue to Hold EXAS Stock in Your Portfolio Now? - Yahoo Finance
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook - AD HOC NEWS
Exact Sciences Corp. Stock Tests Investor Patience as Diagnostics Story Enters a New Act - AD HOC NEWS
Exact Sciences accelerates executive bonuses and equity awards ahead of merger By Investing.com - Investing.com Australia
Exact Sciences accelerates executive bonuses and equity awards ahead of merger - Investing.com Nigeria
Harbor Capital Advisors Inc. Sells 29,990 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation (NASDAQ:EXAS) Given Average Recommendation of "Hold" by Analysts - MarketBeat
What Are the Top 20 Gastroenterology Companies in 2025? - Global Growth Insights
Is Exact Sciences Stock Still Attractive After a 78.1% Surge in 2025? - simplywall.st
How The Abbott Takeover Is Rewriting Exact Sciences Story And Valuation - Yahoo Finance
Gastrointestinal Diagnostics (GI) Market to Reach $5.8 Billion by 2030 - GlobeNewswire Inc.
Is Exact Sciences (EXAS) Still Undervalued After Its Recent Share Price Surge? - simplywall.st
Holocene Advisors LP Acquires 1,404,086 Shares of Exact Sciences Corporation $EXAS - MarketBeat
EXAS Quantitative Stock Analysis - Nasdaq
Why Exact Sciences Stock Surged Today - AOL.com
Exact Sciences Corporation $EXAS Shares Sold by Bellevue Group AG - MarketBeat
Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer - MSN
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS - The AI Journal
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect - Business Wire
Quantbot Technologies LP Invests $604,000 in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences (NASDAQ:EXAS) Sets New 52-Week HighTime to Buy? - MarketBeat
Exact Sciences stock reaches 52-week high at 101.89 USD By Investing.com - Investing.com South Africa
Exact Sciences stock reaches 52-week high at 101.89 USD - Investing.com
Exact Sciences Showcases Breadth of Early Detection and Treatmen - GuruFocus
Peninsula company rides blank check to Wall Street after raising more than $1 billion as a startup - The Business Journals
Baird Financial Group Inc. Sells 30,218 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Assessing Exact Sciences After 77.5% YTD Surge and Abbott Deal Outlook - Yahoo Finance
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Cancer detection firm Freenome to go public via $330 million SPAC deal - statnews.com
Cancer blood test maker Freenome going public with $330M SPAC - BioWorld MedTech
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk - simplywall.st
Has Exact Sciences Rally of Over 50% Left Room for Further Upside? - simplywall.st
OMERS ADMINISTRATION Corp Sells 113,387 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Published on: 2025-12-04 02:35:05 - Newser
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? - Yahoo Finance
Schroder Investment Management Group Raises Stock Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Exact Sciences (NASDAQ:EXAS) Sees Large Volume IncreaseHere's Why - MarketBeat
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.56%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):